H-1B sponsorship profile: Novartis Gene Therapies, Inc. Across U.S. Department of Labor LCA disclosures, Novartis Gene Therapies, Inc filed 14 Labor Condition Applications covering 14 H-1B worker positions between fiscal year 2023 and fiscal year 2026. The employer’s DOL certification rate sits at 100% (14 certified of 14 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Novartis Gene Therapies, Inc’s H-1B petitions range from $73,050 at the low end to $115,482 at the high end, with a petition-weighted average of $96,762. That range reflects the mix of occupations the company sponsors, led by Specialist, Quality Control (3 petitions at $100,748 avg), followed by Manufacturing Quality Assurance Specialist and Senior Engineer, Manufacturing Science. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Novartis Gene Therapies, Inc is headquartered in East Hanover , NJ under NAICS code 32541, and places H-1B workers across 2 states, most heavily in NC, IL. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Novartis Gene Therapies, Inc ranks. By H-1B petition volume, Novartis Gene Therapies, Inc is #13,107 of 119,880 employers nationally and #1,173 of 5,818 employers headquartered in NJ. Both ranks are computed live from the same underlying petition counts, not a separate estimate.